Report cover image

Intravenous Immunoglobulins Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Publisher Fortune Business Insights Pvt. Ltd.
Published Jan 01, 2025
Length 145 Pages
SKU # FOB19847119

Description

Growth Factors of Intravenous Immunoglobulins Market

The global Intravenous Immunoglobulin (IVIG) market is witnessing significant expansion, driven by rising demand for immunotherapy treatments and an increasing prevalence of immune deficiency disorders. IVIG, a crucial plasma-derived product, is used ttreat various conditions, including primary immunodeficiency (PI), autoimmune diseases, and neurological disorders. With growing research and development efforts, the market is set texperience steady growth over the coming years.

Market Size and Growth Projections

According tthe latest report from Fortune Business Insights, the IVIG market was valued at $9.79 billion in 2017 and is projected treach $24.53 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 6.3% during the forecast period. The demand for IVIG is increasing due timproved diagnostic capabilities, a rise in plasma collection efforts, and greater healthcare accessibility in emerging economies.

Key Drivers of Market Growth

1. Rising Prevalence of Immunodeficiency Disorders

One of the primary factors propelling market growth is the increasing number of patients suffering from immunodeficiency disorders such as primary immunodeficiency (PI) and secondary immunodeficiencies caused by chemotherapy, organ transplants, and chronic infections. The rising awareness and improved diagnostic rates have contributed tan expanded patient base requiring IVIG therapy.

2. Advancements in Plasma Fractionation and Manufacturing

Technological advancements in plasma fractionation and IVIG production have enhanced product safety and efficacy, driving its adoption. Companies are investing in next-generation purification techniques timprove the quality of IVIG formulations, reducing adverse reactions and increasing patient compliance.

3. Increased Research in Neurological Applications

Beyond immunodeficiency disorders, IVIG is gaining recognition for its therapeutic potential in neurological diseases such as Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis. Several clinical trials are evaluating IVIG’s effectiveness in treating Alzheimer’s disease, further expanding market opportunities.

4. Expanding Healthcare Infrastructure in Emerging Markets

The demand for IVIG is rising in Asia-Pacific, Latin America, and the Middle East due timproving healthcare infrastructure, increased government initiatives, and a higher focus on rare disease treatments. Countries such as China, India, and Brazil are witnessing an upsurge in IVIG usage due tbetter accessibility and affordability.

Challenges Facing the IVIG Market

1. High Cost and Limited Plasma Supply

A significant challenge in the IVIG market is the high cost of treatment, which limits accessibility, especially in lower-income regions. Additionally, IVIG production is dependent on plasma donations, and fluctuations in plasma supply can impact market stability.

2. Stringent Regulatory Approvals

IVIG products are subject trigorous regulatory frameworks tensure safety and efficacy. Compliance with these standards requires significant investments from manufacturers, which can slow down product approvals and market entry.

Competitive Landscape

The IVIG market is dominated by key players engaged in product innovations, mergers, and acquisitions tstrengthen their market presence. Leading companies include:
  • Grifols S.A.
  • CSL Behring
  • Takeda Pharmaceutical Company Limited (Shire)
  • Octapharma AG
  • Kedrion Biopharma
These companies are focusing on expanding plasma collection networks and launching new IVIG formulations tcater tthe growing patient demand.

Future Outlook and Opportunities

1. Personalized and Targeted Therapies

Ongoing research in biopharmaceuticals and personalized medicine is expected tenhance IVIG formulations, improving treatment outcomes. The development of subcutaneous immunoglobulin (SCIG) therapy is alsgaining traction, offering patients more convenient administration methods.

2. Strategic Collaborations and Expansions

Market players are investing in plasma collection centers, R&D facilities, and global expansion strategies tstrengthen their supply chains and improve product availability. Increased collaborations with research institutions will likely lead tnovel IVIG applications.

3. Emerging Markets as Growth Hubs

With the increasing burden of immune-related diseases in developing countries, governments and healthcare providers are working towards improving IVIG accessibility through subsidies and insurance coverage. This presents a lucrative opportunity for market expansion.

Conclusion

The Intravenous Immunoglobulin (IVIG) market is on a growth trajectory, driven by increasing disease prevalence, technological advancements, and expanding healthcare access. While challenges such as high costs and supply limitations persist, ongoing innovations and strategic initiatives are expected tsustain market momentum. With a projected market size of $24.53 billion by 2032, IVIG continues tbe a vital component in immunotherapy treatments, promising better healthcare outcomes worldwide.

SEGMENTATIO
  • DETAILS

    • By Indication <>
  • Primary Immunodeficiency
    • <>
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    • <>
  • Guillain-Barré Syndrome (GBS)
    • <>
  • Immune Thrombocytopenic Purpura (ITP)
    • <>
  • Multifocal Motor Neuropathy (MMN)
    • <>
  • Others
    • By Form <>
  • Liquid
    • <>
  • Lyophilized
    • By End User <>
  • Hospitals
    • <>
  • Clinics
    • <>
  • Homecare
    • By Geography <>
  • North America (the U.S., and Canada)
    • <>
  • Europe (Germany, U.K., France, Italy, Spain, Scandinavia, and Rest of Europe)
    • <>
  • Asia Pacific (China, India, Japan, Australia, South East Asia, and Rest of Asia Pacific)
    • <>
  • Latin America (Brazil, Mexico, and Rest of Latin America
    • <>
  • Middle East & Africa (GCC, South Africa, and Rest of Middle East & Africa)


    • Please Note: It will take 5-6 business days to complete the report upon order confirmation.

    Table of Contents

    145 Pages
    1. Introduction
    1.1. Research Scope
    1.2. Market Segmentation
    1.3. Research Methodology
    1.4. Definitions and Assumptions
    2. Executive Summary
    3. Market Dynamics
    3.1. Market Drivers
    3.2. Market Restraints
    3.3. Market Opportunities
    4. Key Insights
    4.1. Pipeline Analysis
    4.2. Overview of Regulatory Scenario by Key Regions
    4.3. Key Industry Developments
    4.4. Number (Estimated) of Primary Immunodeficiency (PI) Patients by Key Countries
    4.5. Overview of Reimbursement Scenario
    5. Global Intravenous Immunoglobulins Market Analysis, Insights and Forecast, 2015-2026
    5.1. Key Findings / Summary
    5.2. Market Analysis, Insights and Forecast – By Indication
    5.2.1. Primary Immunodeficiency
    5.2.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    5.2.3. Guillain-Barré Syndrome (GBS)
    5.2.4. Immune Thrombocytopenic Purpura (ITP)
    5.2.5. Multifocal Motor Neuropathy (MMN)
    5.2.6. Others
    5.3. Market Analysis, Insights and Forecast – By Form
    5.3.1. Liquid
    5.3.2. Lyophilized
    5.4. Market Analysis, Insights and Forecast – By End User
    5.4.1. Hospitals
    5.4.2. Clinics
    5.4.3. Homecare
    5.5. Market Analysis, Insights and Forecast – By Region
    5.5.1. North America
    5.5.2. Europe
    5.5.3. Asia Pacific
    5.5.4. Latin America
    5.5.5. Middle East & Africa
    6. North America Intravenous Immunoglobulins Market Analysis, Insights and Forecast, 2015-2026
    6.1. Key Findings / Summary
    6.2. Market Analysis – By Indication
    6.2.1. Primary Immunodeficiency
    6.2.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    6.2.3. Guillain-Barré Syndrome (GBS)
    6.2.4. Immune Thrombocytopenic Purpura (ITP)
    6.2.5. Multifocal Motor Neuropathy (MMN)
    6.2.6. Others
    6.3. Market Analysis – By Form
    6.3.1. Liquid
    6.3.2. Lyophilized
    6.4. Market Analysis – By End User
    6.4.1. Hospitals
    6.4.2. Clinics
    6.4.3. Homecare
    6.5. Market Analysis – By Country
    6.5.1. U.S.
    6.5.2. Canada
    7. Europe Intravenous Immunoglobulins Market Analysis, Insights and Forecast, 2015-2026
    7.1. Key Findings / Summary
    7.2. Market Analysis – By Indication
    7.2.1. Primary Immunodeficiency
    7.2.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    7.2.3. Guillain-Barré Syndrome (GBS)
    7.2.4. Immune Thrombocytopenic Purpura (ITP)
    7.2.5. Multifocal Motor Neuropathy (MMN)
    7.2.6. Others
    7.3. Market Analysis – By Form
    7.3.1. Liquid
    7.3.2. Lyophilized
    7.4. Market Analysis – By End User
    7.4.1. Hospitals
    7.4.2. Clinics
    7.4.3. Homecare
    7.5. Market Analysis – By Country/ Sub-Region
    7.5.1. U.K.
    7.5.2. Germany
    7.5.3. France
    7.5.4. Spain
    7.5.5. Italy
    7.5.6. Scandinavia
    7.5.7. Rest of Europe
    8. Asia Pacific Intravenous Immunoglobulins Market Analysis, Insights and Forecast, 2015-2026
    8.1. Key Findings / Summary
    8.2. Market Analysis – By Indication
    8.2.1. Primary Immunodeficiency
    8.2.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    8.2.3. Guillain-Barré Syndrome (GBS)
    8.2.4. Immune Thrombocytopenic Purpura (ITP)
    8.2.5. Multifocal Motor Neuropathy (MMN)
    8.2.6. Others
    8.3. Market Analysis – By Form
    8.3.1. Liquid
    8.3.2. Lyophilized
    8.4. Market Analysis – By End User
    8.4.1. Hospitals
    8.4.2. Clinics
    8.4.3. Homecare
    8.5. Market Analysis – By Country/ Sub-Region
    8.5.1. Japan
    8.5.2. China
    8.5.3. India
    8.5.4. Australia
    8.5.5. Southeast Asia
    8.5.6. Rest of Asia Pacific
    9. Latin America Intravenous Immunoglobulins Market Analysis, Insights and Forecast, 2015-2026
    9.1. Key Findings / Summary
    9.2. Market Analysis – By Indication
    9.2.1. Primary Immunodeficiency
    9.2.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    9.2.3. Guillain-Barré Syndrome (GBS)
    9.2.4. Immune Thrombocytopenic Purpura (ITP)
    9.2.5. Multifocal Motor Neuropathy (MMN)
    9.2.6. Others
    9.3. Market Analysis – By Form
    9.3.1. Liquid
    9.3.2. Lyophilized
    9.4. Market Analysis – By End User
    9.4.1. Hospitals
    9.4.2. Clinics
    9.4.3. Homecare
    9.5. Market Analysis – By Country/ Sub-Region
    9.5.1. Brazil
    9.5.2. Mexico
    9.5.3. Rest of Latin America
    10. Middle East & Africa Intravenous Immunoglobulins Market Analysis, Insights and Forecast, 2015-2026
    10.1. Key Findings / Summary
    10.2. Market Analysis – By Indication
    10.2.1. Primary Immunodeficiency
    10.2.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    10.2.3. Guillain-Barré Syndrome (GBS)
    10.2.4. Immune Thrombocytopenic Purpura (ITP)
    10.2.5. Multifocal Motor Neuropathy (MMN)
    10.2.6. Others
    10.3. Market Analysis – By Form
    10.3.1. Liquid
    10.3.2. Lyophilized
    10.4. Market Analysis – By End User
    10.4.1. Hospitals
    10.4.2. Clinics
    10.4.3. Homecare
    10.5. Market Analysis – By Country/ Sub-Region
    10.5.1. GCC Countries
    10.5.2. South Africa
    10.5.3. Rest of Middle East & Africa
    11. Competitive Analysis
    11.1. Key Industry Developments
    11.2. Global Market Share Analysis (2018)
    11.3. Competition Dashboard
    11.4. Comparative Analysis – Major Players
    11.5. Company Profiles (Overview, Products & Services, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
    11.5.1. Shire (Takeda Pharmaceutical Company Limited)
    11.5.1.1. Overview,
    11.5.1.2. Products & Services,
    11.5.1.3. SWOT Analysis,
    11.5.1.4. Recent Developments,
    11.5.1.5. Strategies,
    11.5.1.6. Financials (Based on Availability)
    11.5.2. CSL Behring
    11.5.2.1. Overview,
    11.5.2.2. Products & Services,
    11.5.2.3. SWOT Analysis,
    11.5.2.4. Recent Developments,
    11.5.2.5. Strategies,
    11.5.2.6. Financials (Based on Availability)
    11.5.3. Grifols, S.A.
    11.5.3.1. Overview,
    11.5.3.2. Products & Services,
    11.5.3.3. SWOT Analysis,
    11.5.3.4. Recent Developments,
    11.5.3.5. Strategies,
    11.5.3.6. Financials (Based on Availability)
    11.5.4. Kedrion S.p.A
    11.5.4.1. Overview,
    11.5.4.2. Products & Services,
    11.5.4.3. SWOT Analysis,
    11.5.4.4. Recent Developments,
    11.5.4.5. Strategies,
    11.5.4.6. Financials (Based on Availability)
    11.5.5. Octapharma
    11.5.5.1. Overview,
    11.5.5.2. Products & Services,
    11.5.5.3. SWOT Analysis,
    11.5.5.4. Recent Developments,
    11.5.5.5. Strategies,
    11.5.5.6. Financials (Based on Availability)
    11.5.6. Bio Products Laboratory Ltd.
    11.5.6.1. Overview,
    11.5.6.2. Products & Services,
    11.5.6.3. SWOT Analysis,
    11.5.6.4. Recent Developments,
    11.5.6.5. Strategies,
    11.5.6.6. Financials (Based on Availability)
    11.5.7. Biotest AG
    11.5.7.1. Overview,
    11.5.7.2. Products & Services,
    11.5.7.3. SWOT Analysis,
    11.5.7.4. Recent Developments,
    11.5.7.5. Strategies,
    11.5.7.6. Financials (Based on Availability)
    11.5.8. China Biologic Products Holdings, Inc.
    11.5.8.1. Overview,
    11.5.8.2. Products & Services,
    11.5.8.3. SWOT Analysis,
    11.5.8.4. Recent Developments,
    11.5.8.5. Strategies,
    11.5.8.6. Financials (Based on Availability)
    11.5.9. LFB SA
    11.5.9.1. Overview,
    11.5.9.2. Products & Services,
    11.5.9.3. SWOT Analysis,
    11.5.9.4. Recent Developments,
    11.5.9.5. Strategies,
    11.5.9.6. Financials (Based on Availability)
    11.5.10. Shanghai RAAS Blood Products Co., Ltd.
    11.5.10.1. Overview,
    11.5.10.2. Products & Services,
    11.5.10.3. SWOT Analysis,
    11.5.10.4. Recent Developments,
    11.5.10.5. Strategies,
    11.5.10.6. Financials (Based on Availability)
    12. Strategic Recommendations

    Pricing

    Currency Rates
    How Do Licenses Work?

    How Do Licenses Work?

    The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

    • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

    • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

    • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

    • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

    • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

    License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

    Head shot

    Questions or Comments?

    Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
    Chat Now
    Contact Us